Taking aim at translation for tumor therapy.

Abstract

Increased cap-dependent mRNA translation rates are frequently observed in human cancers. Mechanistically, many human tumors often overexpress the cap binding protein eukaryotic translation initiation factor 4E (eIF4E), leading to enhanced translation of numerous tumor-promoting genes. In this issue of the JCI, Graff and colleagues describe potent antitumor effects using second-generation antisense oligonucleotides for eIF4E (see the related article beginning on page 2638). If their results are recapitulated in a clinical setting, this strategy will provide a promising antitumor therapy with broad-reaching applications.

• Authors: Bryan C Barnhart, M Celeste Simon
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 117 Issue 9 Pg. 2385-8 (Sep 2007) ISSN: 0021-9738 [Print] United States
• PMID: 17786234 (Publication Type: Comment, Journal Article)

Chemical References

• Eukaryotic Initiation Factor-4E

Topics

• Animals
• Down-Regulation
• Eukaryotic Initiation Factor-4E (genetics, metabolism)
• Gene Expression Regulation, Neoplastic
• Humans
• Neoplasms (genetics, metabolism, pathology, therapy)
• Protein Biosynthesis (genetics)